Study Title

A First-in-Human Study of 89Zr-DFO-REGN5054 (Anti-CD8) Positron Emission Tomography in Patients With Solid Malignancies Treated With Cemiplimab

Study Details

Description:

The primary objective of the study is to determine the safety and tolerability of 89Zr-DFO-REGN5054 alone and in combination with cemiplimab.

Sponsor:

Regeneron Pharmaceuticals

Contacts:

Clinical Trials Administrator

clinicaltrials@regeneron.com

844-734-6643

Government Study Link:

NCT05259709 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468